NEW YORK, Jan. 28, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies (OTC:AXIM) is proud to announce the following finance and community outreach-focused additions to the Company’s advisory board:
- Seth Yakatan – Industry-Leading Biotech Finance Consultant
- Marvin Washington – Retired NFL Star and Sports Advisor
Photos accompanying this release are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/34e3bb95-1d77-4e49-a5ff-1a854a5d475d
http://www.globenewswire.com/NewsRoom/AttachmentNg/0958ec76-06fb-4cd4-b95a-8282127ca412
“We are extremely fortunate to have attracted the proven industry leadership of Seth Yakatan and Marvin Washington,” states Dr. George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM® Biotechnologies, Inc. “Both support AXIM’s mission and their added expertise will assist the Company in: affordably introducing new proprietary cannabis-based medicinal delivery methods, explaining the importance of solutions for health, wellness and sports injury prevention, and conveying to the public AXIM’s role in restoring hemp to the global economy.”
AXIM® Biotech is currently in clinical trials for its patented cannabinoid-release chewing gum, MedChew RX™, for pain and spasticity with multiple sclerosis (MS). Another initiative of AXIM® Biotech is to determine the effects of hemp-based cannabinoids on neurodegenerative conditions including post-traumatic stress disorder (PTSD) through research and clinical trials.
With more than two decades of financial industry experience, Yakatan’s background as a corporate finance professional includes: actively supporting small cap and major companies in achieving corporate, financing and asset monetization objectives through the successful structuring and management of strategic transactions and investments totaling more than $7 billion in value. Now focused on maximizing AXIM® Biotech’s fiscal capabilities while ushering in cannabis’ return to the global healthcare industry, Yakatan is on AXIM®’s Advisory Board and is a consultant to the Company. Click here for additional details on Yakatan’s background.
Washington is guiding AXIM® Biotech in the role of Sports Advisor. The Super Bowl star has gone on the record discussing contact sports and his first-hand experience on the effects of head injuries, based on his stellar 11-year career in the NFL. He is actively explaining to the public and news media research behind the use of the non-psychoactive cannabinoid - cannabidiol (CBD) - to proactively address neuroprotection. Washington addresses members of the news media and industry groups including: sports (recreational, youth, collegiate and professional), military service members, military veterans, and individuals battling concussions and brain injury around the world.
Washington states, “I am very happy to be added to AXIM’s Board, as the Company continues to work to be one of the leaders in the medical cannabis industry.” Click here for additional details on Washington’s background.
Dr. Anastassov continues, “AXIM Biotech is greatly appreciative of our entire Board of Advisors for their roles in advancing cannabinoid-based research and product development.”
Focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.), AXIM® Biotech is on a mission to find solutions for conditions for which there is currently no effective treatment including: MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), psychosis, PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS, and Crohn’s disease.
Setting a major global example for “green” innovation and manufacturing, the plans of AXIM® Biotech include creating a net negative carbon footprint in the environment.
AXIM® Biotech has been featured by media outlets including: Reuters, Yahoo! Finance, Marketwatch, ABC, NBC, CBS, Telemundo, WGN, Univision, Marijuana Investor News, FOX Business, MainStreet.com, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News. For more information, visit AXIM Biotech’s website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotechnologies.com or call 888-829-0070.
About AXIM® Biotechnologies:
AXIM® Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM® Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.